Role of hormones in hypoactive sexual desire disorder and current treatment

Over the decades,female sexual dysfunction (fsd) has grown to be an increasingly potential problem that complicates the quality of life among women. in the current review,fsd refers to recurrent and persistent problems with sexual orgasm,desire,or response. one of the most common subtypes of fsd that has evoked increased research interest in the scientific community is hyposexuality. today,there is a consensus that hyposexuality is a multifactorial condition that manifests with reduced sexual desire resulting in significant interpersonal distress. the objective of the current review was to examine how hormonal profile triggers propagate hypoactive sexual desire disorder (hsdd),and to highlight effective treatment interventions that can be used to manage the condition. the current review describes hsdd as a sexual dysfunction characterized by the absence or lack of sexual desire and fantasies for sexual activities. the review argues that even if the role of sexual hormones is essential in modulating hsdd through therapeutic interventions,an effective comprehension of the biologic mechanisms underlying hsdd is necessary. there is a consensus in the literature that hsdd still poses significant challenges due to the lack of properly formulated treatment regimens and absence of clear clinical guidelines. that is,a better intervention consisting of both psycho-relational and biologic aspects is compulsory if tailored management and accurate diagnosis of hsdd in clinical practice are to be realised. the review concludes that,to date,a reliable clinical intervention to manage hyposexuality is still absent and more interventions,in terms of safety and efficacy,are required. thus,additional investigation is required to document precise hormonal or non-hormonal pharmacotherapeutic agents for individualised care among patients with hsdd. © 2017 by the turkish-german gynecological education and research foundation.